Clinical Trial Update: A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults [Phase 3]

View source ↗

Summary

Phase 3 trial of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in treatment-naïve adults with Hepatitis C Genotype 1b completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (ombitasvir/paritaprevir/ritonavir/dasabuvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-12-13